Results

Total Results: 1,643 records

Showing results for "factor".

81. Rapid Response_Linking Dental Services to Treatment Outcomes for Chronic Kidney Disease: A Rapid Response Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-outcomes-chronic-kidney-rapid-research.pdf
    November 01, 2024 - Indeed, recent findings have identified that periodontitis is a risk factor for eGFR decline, and dental … ND: no dialysis; PD: peritoneal dialysis; TIBC: Total iron binding capacity; TNF-α: Tumor Necrosis Factor … treatment; OHI: Oral hygiene instruction; RCT: randomized controlled trial; TNF-α: Tumor Necrosis Factor … treatment; OHI: Oral hygiene instruction; RCT: randomized controlled trial; TNF-α: Tumor Necrosis Factor … Effects of Non-Surgical Periodontal Therapy on Serum Inflammatory Factor High-Sensitive C- Reactive

82. Rheumatoid-Arthritis-Medicine Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_executive.pdf
    April 01, 2012 - leflunomide, methotrexate [MTX], and sulfasalazine), and biologic DMARDs (five anti-tumor necrosis factor … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Abbreviations ACR American College of Rheumatology Anti-TNF Anti-tumor necrosis factor drugs CDER Center

83. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0320_06-17-2009.pdf
    January 01, 2009 - Can FLC reliably be used as an independent risk factor for progression to MM in MGUS patients?

84. Ebell_Presentation_REVISED_FINAL (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/use_of_handheld_ebell_presentation.pdf
    January 01, 2009 -  based  on:   o Counting  (i.e.  1  point  per  clinical  finding  or  risk  factor

85. Bladder-Cancer-Non-Muscle-Invasive Research-Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/bladder-cancer-non-muscle-invasive_research-protocol.pdf
    July 21, 2014 - taking into account diagnostic testing, management, and long term follow up.4 The most common risk factor … using techniques such as fluorescence in situ hybridization [FISH] assay or mRNA); fibroblast growth factor … cytokeratin fragments (e.g., CYFRA 21-1, TPA, TPS); survivin; telomerase; vascular endothelial growth factor … matrix protein or nmp22 or fluorescence in situ hybrid$ or (fish adj assay$) or fibroblast growth factor … cyfra 21-1 or (cytokerat$ adj3 (tpa or tps)) or survivin or telomeras$ or vascular endothelial growth factor

86. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
    March 01, 2013 - Randomized Controlled Trial; SCEPC: Southern California Evidence-based Practice Center; TNF: Tumor Necrosis Factor … Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection … and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor … Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including … Randomized Controlled Trial; SCEPC: Southern California Evidence-based Practice Center; TNF: Tumor Necrosis Factor

87. Evidence Report on the (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/vte-protocol-8-4-10.pdf
    February 01, 2008 - injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … what is the relative impact of injectable antithrombotic agents (LMWH vs. unfractionated heparin vs. factor … Factor Xa Inhibitors Rivaroxiban (Xarelto®) Ortho-McNeil- Janssen Investigational drug, not … methods of thromboprophylaxis versus control or compare injectable antithrombotic agents (LMWH, UFH, factor

88. Evidence Report on the (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/blood-clots-hip-knee-surgery_research-protocol.pdf
    February 01, 2008 - injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … injectable low molecular weight heparins (LMWH), injectable unfractionated heparin, injectable or oral factor … what is the relative impact of injectable antithrombotic agents (LMWH vs. unfractionated heparin vs. factor … Factor Xa Inhibitors Rivaroxiban (Xarelto®) Ortho-McNeil- Janssen Investigational drug, not … methods of thromboprophylaxis versus control or compare injectable antithrombotic agents (LMWH, UFH, factor

89. Hemophilia | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/health-topics/hemophilia

90. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Esbriet®) is a synthetic pyridone analogue reported to inhibit the synthesis of transforming growth factor … receptors purportedly involved in the pathogenesis of IPF, including vascular endothelial growth factor … receptor 2 (VEGFR2), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor … receptor kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth … factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).

91. Misuse of Prescription Stimulants in Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/misuse-prescription-protocol.pdf
    September 13, 2024 - Quality In Prognosis Studies (QUIPS) tool13 which covers study participation, attrition, prognostic factor … Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework

92. PowerPoint Presentation (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-frameworks.ppt
    June 01, 2012 - screen-film mammography in breast cancer screening Project 2 (add-on test): Human epidermal growth factor … replacement for screening film mammography. - The add-on test example uses a human epidermal growth factor … Initial ambiguous claim: Amplification and protein expression assays of the human epidermal growth factor … It involves the use of a human epidermal growth factor receptor 2 (HER2) gene amplification assay after … a refined claim that patients with equivocal results for over expression of human epidermal growth factor

93. PowerPoint Presentation (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-frameworks.ppt
    June 01, 2012 - screen-film mammography in breast cancer screening Project 2 (add-on test): Human epidermal growth factor … replacement for screening film mammography. - The add-on test example uses a human epidermal growth factor … Initial ambiguous claim: Amplification and protein expression assays of the human epidermal growth factor … It involves the use of a human epidermal growth factor receptor 2 (HER2) gene amplification assay after … a refined claim that patients with equivocal results for over expression of human epidermal growth factor

94. - (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_appendixes.pdf
    January 01, 2009 - Modulating effect of human growth hormone on tumour necrosis factor-alpha and interleukin- 1beta. … Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor … Insulin-Like Growth Factor 1 (IGF-1): Protein hormone responsible for growth and development. … growth factors including insulin-like growth factor 1 (IGF-1). … Stature as a prognostic factor in cystic fibrosis survival.

95. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia_executive.pdf
    May 01, 2006 - Neither higher than recommended target Hb nor any other single patient- or treatment- related factor … select patients or predict responses to treatment Available evidence does not identify any single factor

96. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
    December 11, 2012 - Fondaparinux is an indirect factor Xa inhibitor that is injected subcutaneously on a daily basis. … OR effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept … OR effient[tw] OR ticagrelor[supplementary concept] OR ticagrelor[tw] OR brilinta[tw] 121676 #3 factor … xa[mesh] OR "factor xa inhibitor"[tw] OR "factor xa inhibitors"[tw] OR rivaroxaban[Supplementary Concept

97. Dia 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
    January 01, 2011 - scenarios and if a respondent picks all these scenarios we can assume Thai food is an important factor

98. Conducting Quantitative Synthesis when Comparing Medical Interventions: AHRQ and the Effective Health Care Program (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-quantitative-synthesis_methods.pdf
    October 01, 2010 - events become more frequent (5 percent to10 percent), the Mantel-Haenszel method (without correction factor … Considerations of correction factor for studies with zero events in one arm. … method, the Mantel-Haenszel method, or a logistic regression approach, without adding a correction factor … For the Mantel-Haenszel method, a correction factor of 0.5 is not recommended but using no correction … factor or alternative correction factors could be considered, and investigated in sensitivity analyses

99. Conducting Quantitative Synthesis when Comparing Medical Interventions: AHRQ and the Effective Health Care Program (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_conductingquantitativesynthesis.pdf
    October 01, 2010 - events become more frequent (5 percent to10 percent), the Mantel-Haenszel method (without correction factor … Considerations of correction factor for studies with zero events in one arm. … method, the Mantel-Haenszel method, or a logistic regression approach, without adding a correction factor … For the Mantel-Haenszel method, a correction factor of 0.5 is not recommended but using no correction … factor or alternative correction factors could be considered, and investigated in sensitivity analyses

100. Rapid Response_The Association Between Outcomes and Dental Services in Persons With Autoimmune Disease Treated With Biologics and Other Immunosuppressants: A Rapid Response Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/autoimmune-disease-rapid-research.pdf
     November 01, 2024 - There is weak evidence for lowering of other inflammatory markers like Tumor necrosis factor alpha … weak evidence for other outcomes like anti-citrullinated protein autoantibodies (ACPAs), rheumatoid factor … • Other outcomes: We find weak evidence for other outcomes like ACPAs, rheumatoid factor, life impact … area and severity index; RA: rheumatoid arthritis; RCT: randomized controlled trial; RF: rheumatoid factor … periodontal treatment; RA: rheumatoid arthritis; RCT: randomized controlled trial; RF: rheumatoid factor